A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01960010 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

403

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes

Interventions

DRUG: MIM-D3 Ophthalmic Solution
DRUG: Vehicle

Sponsor

Mimetogen Pharmaceuticals USA, Inc.